Fiducial Marker Articles & Analysis: Older
6 news found
C4 Imaging LLC, an early-stage medical device company, has completed its latest round of financing, which included a significant institutional component. Institutional investment was led by Stoneworth Financial, LLC, a Houston based investment banking group. Proceeds will be used for growth capital, targeted at accelerating clinical adoption of C4 Imaging’s portfolio of FDA cleared products ...
C4 Imaging LLC is pleased to announce that Isoray Medical, Inc. (NYSE American: ISR) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of C4 Imaging’s Sirius positive-signal MRI (Magnetic Resonance Imaging) Markers with Isoray’s Cesium-131, brachytherapy seeds. Sirius is implanted during the treatment of prostate cancer with brachytherapy and is used ...
VeraForm® placement to assist with localization and delivery of adjuvant radiation Historically, lumpectomies resulted in a scar immediately over the lumpectomy site, dictating delivery of adjuvant radiation on scar location, and frequently on the presence of a seroma. Currently, the question persists as to the optimal means to help direct the radiation oncologist to effectively deliver ...
Our Medical Director of the Oncology Breast Program, Dr. Beth DuPree, was first in the U.S. to adopt VeraForm, a continuous, radiopaque 3D tissue marker. Within months, its utility led to quick integration into our program’s standard daily practice. Like all centers today, patient satisfaction is a focal point and to date, we have seen no complications or toxicities by any criteria (e.g., ...
It’s always been distressing to explain to surgeons that their meticulously placed lumpectomy clips are much less useful to radiation oncologists than they originally perceived. Maybe it’s because of the desperate appreciation that radiation oncologists express when even one clip is left behind. In this current era of de-escalating therapies, patients receiving breast radiation ...
C4 Imaging LLC announces U.S. Food and Drug Administration 510(k) clearance of its third major product, the Multimodality C4 Fiducial Marker. This novel positive-signal MRI marker will be implanted into patients in situations where the location of specific anatomy, normal or diseased, needs to be marked for a future medical procedure. The device can be visualized using MRI, CT or x-ray, and ...